Fundraising Overview - The company, Guoke Hengtai (Beijing) Medical Technology Co., Ltd., has been approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with RMB 227.504 million being excess funds [1] - The funds were fully received by July 5, 2023, and are being managed in a dedicated account with a tripartite supervision agreement established with the underwriter and the bank [1] Use of Funds - The company plans to use up to RMB 92.75 million of the idle funds temporarily to supplement working capital, with a usage period not exceeding 12 months from the board's approval date [2] - The dedicated account for the idle funds has been opened at the Bank of China, specifically for the temporary use of these funds [2] Tripartite Supervision Agreement - The tripartite agreement involves the company, Bank of China, and the underwriter, Great Wall Securities, to ensure proper management and protection of investor rights [2][3] - The agreement stipulates that any withdrawal exceeding RMB 50 million or 20% of the net amount must be reported to the underwriter [6] - The underwriter has the right to supervise the use of funds and can request information from the bank regarding the dedicated account [5][6] Compliance and Legal Framework - The agreement is governed by relevant Chinese laws, and any disputes will be resolved through negotiation or, if necessary, litigation [7] - The company is required to comply with the regulations set forth by the Shenzhen Stock Exchange and the China Securities Regulatory Commission regarding the management of raised funds [2][5]
国科恒泰: 关于签订募集资金三方监管协议的公告